annb0t
Top 20
LONDON, UK / ACCESSWRE / December 19, 2022 / Kazia Therapeutics has announced a research collaboration with QIMR Berghofer Medical Research Institute (an Australia-based cancer research center) to investigate the utility of its lead asset, paxalisib (PI3K/mTOR inhibitor) in solid tumors. The collaboration plans to build on previously conducted research, including the potential use of paxalisib as an immune modulator in solid tumors. We note that the company recently announced encouraging data in...
>>> Read more: Kazia Therapeutics (KZIA): Collaboration May Expand Utility to Combo Therapies
>>> Read more: Kazia Therapeutics (KZIA): Collaboration May Expand Utility to Combo Therapies
